PriceTargets.com logo
Breaking Now: Biden's Disturbing Plan to "Reset" America
From Legacy Research
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.

NASDAQ:PLRX - Pliant Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.50
  • Forecasted Upside: 52.02 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$29.93 As of 04/16/2021 01:00 AM ET
▼ -0.71 (-2.32%)
1 month | 3 months | 12 months
Get New Pliant Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.50
▲ +52.02% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $45.50, with a high forecast of $52.00 and a low forecast of $40.00. The average price target represents a 52.02% upside from the last price of $29.93.
Breaking Now: Biden's Disturbing Plan to "Reset" America
From Legacy Research
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Pliant Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2021CitigroupInitiated CoverageBuyLow
i
4/5/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$52.00High
i
8/12/2020Needham & Company LLCReiterated RatingBuy$40.00High
i
6/29/2020CowenInitiated CoverageOutperformHigh
i
6/29/2020Needham & Company LLCInitiated CoverageBuy$40.00High
i
6/29/2020CitigroupInitiated CoverageBuy$40.00High
i
6/29/2020Piper SandlerInitiated CoverageOverweight$50.00High
i
(Data available from 4/19/2016 forward)
Pliant Therapeutics logo
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avÃ1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $29.93
$28.89
$30.41

50 Day Range

MA: $36.29
$30.23
$40.23

52 Week Range

Now: $29.93
$19.42
$43.92

Volume

65,200 shs

Average Volume

167,217 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pliant Therapeutics?

The following sell-side analysts have issued research reports on Pliant Therapeutics in the last year: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Needham & Company LLC, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for PLRX.

What is the current price target for Pliant Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Pliant Therapeutics in the last year. Their average twelve-month price target is $45.50, suggesting a possible upside of 52.0%. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the highest price target set, predicting PLRX will reach $52.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $40.00 for Pliant Therapeutics in the next year.
View the latest price targets for PLRX.

What is the current consensus analyst rating for Pliant Therapeutics?

Pliant Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLRX will outperform the market and that investors should add to their positions of Pliant Therapeutics.
View the latest ratings for PLRX.

What other companies compete with Pliant Therapeutics?

Other companies that are similar to Pliant Therapeutics include Hutchison China MediTech, Emergent BioSolutions, I-Mab, Arena Pharmaceuticals, Hypera, Agios Pharmaceuticals, Atea Pharmaceuticals, Apellis Pharmaceuticals, Turning Point Therapeutics, Nektar Therapeutics, Legend Biotech, PTC Therapeutics, Insmed, ACADIA Pharmaceuticals and InnovAge.

How do I contact Pliant Therapeutics' investor relations team?

Pliant Therapeutics' physical mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-481-6770 and its investor relations email address is [email protected] The official website for Pliant Therapeutics is pliantrx.com.

Breaking Now: Biden's Disturbing Plan to "Reset" America
From Legacy Research
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.